FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380893735> ?p ?o ?g. }

• W4380893735 abstract "Abstract Background Gantenerumab, a human monoclonal antibody targeting aggregated beta‐amyloid (Abeta), is a potential disease‐modifying treatment for early (prodromal‐to‐mild) Alzheimer’s disease (AD). SCarlet RoAD (SR) (NCT01224106) and Marguerite RoAD (MR) (NCT02051608) were two Phase III trials which assessed the efficacy and safety of subcutaneous (SC), low‐dose gantenerumab in participants with prodromal and mild AD, respectively, for up to 2 years. Following a gap period gantenerumab treatment was continued with uptitration to a dose of 1,200 mg monthly in open‐label extensions (OLE), which demonstrated substantial Abeta removal by positron emission tomography without new or unexpected safety findings. Here, we describe the study design, present baseline characteristics, and safety data from an additional open‐label, multicenter, rollover study, Open RoAD (OR) (NCT04339413), collecting long‐term safety and tolerability data for gantenerumab in participants who completed the SR OLE or MR OLE. Method Participants who completed either OLE study and were treated with doses up to 1,200 mg of gantenerumab for up to 5 years continue to receive the same dose of SC gantenerumab (every 4 weeks [q4w]) for 2 additional years in OR. The primary objective is to evaluate long‐term safety and tolerability by assessing adverse events, including amyloid‐related imaging abnormalities, and injection‐site reactions. Exploratory efficacy objectives include Mini‐Mental State Examination (MMSE) total score. The long‐term effect of gantenerumab on pharmacodynamic measures and biomarkers will also be explored. Result Baseline characteristics Fifty‐nine participants from SR OLE and 56 participants from MR OLE received at least one dose of gantenerumab in OR. The median participant age at baseline was 78 years, and the majority of the participants were female (61%). Sixty‐seven percent of participants were apolipoprotein‐E‐e4 (APOE e4) carriers. The median total MMSE score at baseline was 16. Safety data will be presented. Conclusion The RoAD studies are among the longest‐duration OLEs of an anti‐amyloid monoclonal antibody. Data from the OR study demonstrate that gantenerumab at doses of 1,200 mg administered SC q4w is well tolerated, with no new or unexpected safety findings in patients with early AD." @default.
• W4380893735 created "2023-06-17" @default.
• W4380893735 creator A5005477431 @default.
• W4380893735 creator A5010696933 @default.
• W4380893735 creator A5013158876 @default.
• W4380893735 creator A5020503738 @default.
• W4380893735 creator A5026149226 @default.
• W4380893735 creator A5037459780 @default.
• W4380893735 creator A5038132886 @default.
• W4380893735 creator A5041721537 @default.
• W4380893735 creator A5043928332 @default.
• W4380893735 creator A5044325195 @default.
• W4380893735 creator A5061985039 @default.
• W4380893735 creator A5064214590 @default.
• W4380893735 creator A5068308578 @default.
• W4380893735 creator A5092184771 @default.
• W4380893735 date "2023-06-01" @default.
• W4380893735 modified "2023-09-27" @default.
• W4380893735 title "Open RoAD: Design and baseline characteristics of an open‐label rollover study evaluating long‐term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer’s disease" @default.
• W4380893735 doi "https://doi.org/10.1002/alz.063261" @default.
• W4380893735 hasPublicationYear "2023" @default.
• W4380893735 type Work @default.
• W4380893735 citedByCount "0" @default.
• W4380893735 crossrefType "journal-article" @default.
• W4380893735 hasAuthorship W4380893735A5005477431 @default.
• W4380893735 hasAuthorship W4380893735A5010696933 @default.
• W4380893735 hasAuthorship W4380893735A5013158876 @default.
• W4380893735 hasAuthorship W4380893735A5020503738 @default.
• W4380893735 hasAuthorship W4380893735A5026149226 @default.
• W4380893735 hasAuthorship W4380893735A5037459780 @default.
• W4380893735 hasAuthorship W4380893735A5038132886 @default.
• W4380893735 hasAuthorship W4380893735A5041721537 @default.
• W4380893735 hasAuthorship W4380893735A5043928332 @default.
• W4380893735 hasAuthorship W4380893735A5044325195 @default.
• W4380893735 hasAuthorship W4380893735A5061985039 @default.
• W4380893735 hasAuthorship W4380893735A5064214590 @default.
• W4380893735 hasAuthorship W4380893735A5068308578 @default.
• W4380893735 hasAuthorship W4380893735A5092184771 @default.
• W4380893735 hasBestOaLocation W43808937351 @default.
• W4380893735 hasConcept C126322002 @default.
• W4380893735 hasConcept C197934379 @default.
• W4380893735 hasConcept C2778375690 @default.
• W4380893735 hasConcept C2779134260 @default.
• W4380893735 hasConcept C71924100 @default.
• W4380893735 hasConceptScore W4380893735C126322002 @default.
• W4380893735 hasConceptScore W4380893735C197934379 @default.
• W4380893735 hasConceptScore W4380893735C2778375690 @default.
• W4380893735 hasConceptScore W4380893735C2779134260 @default.
• W4380893735 hasConceptScore W4380893735C71924100 @default.
• W4380893735 hasIssue "S7" @default.
• W4380893735 hasLocation W43808937351 @default.
• W4380893735 hasOpenAccess W4380893735 @default.
• W4380893735 hasPrimaryLocation W43808937351 @default.
• W4380893735 hasRelatedWork W1556562895 @default.
• W4380893735 hasRelatedWork W2057339290 @default.
• W4380893735 hasRelatedWork W2087016115 @default.
• W4380893735 hasRelatedWork W2160729253 @default.
• W4380893735 hasRelatedWork W2335774562 @default.
• W4380893735 hasRelatedWork W2349164817 @default.
• W4380893735 hasRelatedWork W2363981502 @default.
• W4380893735 hasRelatedWork W3189762672 @default.
• W4380893735 hasRelatedWork W4251165208 @default.
• W4380893735 hasRelatedWork W4254901938 @default.
• W4380893735 hasVolume "19" @default.
• W4380893735 isParatext "false" @default.
• W4380893735 isRetracted "false" @default.
• W4380893735 workType "article" @default.